This program provides a discussion and retrospective on the Biden-Harris Administration's achievements and challenges relating to antitrust and the healthcare and pharmaceutical sectors. It explores the successes and challenges of the administration’s approach to healthcare consolidation, drug pricing, and competition policy. Panelists discuss key regulatory changes, enforcement actions, and the broader impact on market competition and healthcare accessibility.
The content of this program does not meet requirements for continuing legal education (CLE) accreditation. You will not receive CLE credit for participating.
